Trials / Completed
CompletedNCT00483470
Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 720 (actual)
- Sponsor
- Sanofi Pasteur, a Sanofi Company · Industry
- Sex
- All
- Age
- 12 Months – 15 Years
- Healthy volunteers
- Accepted
Summary
As per request by the Heath Authorities, the present clinical study will assess the immunogenicity and safety
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Hepatitis A vaccine AVAXIM 80U | 0.5 mL, Intramuscular |
| BIOLOGICAL | Hepatitis A vaccine (HAVRIX 720) | 0.5 mL, Intramuscular |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2008-05-01
- Completion
- 2008-08-01
- First posted
- 2007-06-07
- Last updated
- 2014-01-22
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00483470. Inclusion in this directory is not an endorsement.